Hegseth: Prepare for war to ensure Indo-Pacific peace
May 31 (UPI) -- The United States and its allies won't allow China to dominate the Indo-Pacific region, but do not seek war, Defense Secretary Pete Hegseth said Saturday morning in Singapore.
He addressed regional concerns while speaking during the International Institute for Strategic Studies Shangri-La Dialogue event in Singapore.
Hegseth said the Indo-Pacific region is the United States' "priority theater" and won't allow China to push the United States and its allies out of the region, the Department of Defense announced Friday in a news release.
Instead, deterrence will be the primary tool by which the United States and its allies will counter any aggressive moves made by China, particularly in the South China Sea and against Taiwan.
"As our allies share the burden, we can increase our focus on the Indo-Pacific," Hegseth said, adding that the region is the nation's "priority theater."
He said the futures of the United States and its allies in the Indo-Pacific depend on each other.
"We share a vision of peace and stability, of prosperity and security," Hegseth said, "and we are here to stay."
Common sense and national interests with guide policy making in the region, while respecting mutual self-interests.
President Donald Trump is working to get European nations to do more to increase their respective national security interests instead of largely relying on the United States.
As European nations do more to protect themselves, Hegseth said the United States will be better able to focus on matters in the Indo-Pacific region and do more to thwart Chinese aggression.
"This enables all of us to benefit from the peace and stability that comes with a lasting and strong American presence here in the Indo-Pacific," Hegseth said.
That presence won't come at a cost for the nation's allies, though.
"We are not here to pressure other countries to embrace and adopt our politics or ideology," Hegseth told the audience. "We are all sovereign nations."
He said the United States does not "seek conflict with communist China."
But the United States "will not be pushed out of this critical region," Hegseth added. "And we will not let our allies and partners be subordinated and intimidated."
He said China's leaders are "preparing to use military force to alter the balance of power in the Indo-Pacific," including occupying Taiwan.
Any move by China to take over Taiwan, which China has claimed as part of its sovereign state, would trigger "devastating consequences" for the region and the world, Hegseth told the audience.
"The threat China poses is real, and it could be imminent," he said, adding that the United States and its allies must be prepared with "urgency and vigilance."
If deterrence doesn't work and a fighting war is inevitable, "we are prepared to do what the Department of Defense does best: to fight and win decisively," Hegseth said.
The best way to ensure peace is to prepare for war, "but we have to do this quickly," he said. "We have no time to waste."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
US Dollar: This Week's Labor Data May Offer Support Despite Lingering Trade Fears
The US Dollar fell sharply below 99 amid rising geopolitical and trade tensions. Trump's tariff hike risks reigniting trade wars, raising doubts about the US-China trade truce. Key US economic data this week, especially Friday's nonfarm payrolls, will influence the dollar's path. Looking for actionable trade ideas to navigate the current market volatility? Subscribe here to unlock access to InvestingPro's AI-selected stock winners. The US Dollar started the week with a sharp drop, falling below the 99 level and testing last week's lows. Rising geopolitical tensions, stricter US trade policies, and a packed US economic data schedule have made investors more cautious. Although the dollar saw some small gains last week, it lost those gains quickly this week due to growing political and economic uncertainty. The pressure on the US Dollar is mainly due to President Donald Trump's announcement that tariffs on steel and aluminum imports will rise from 25% to 50% starting June 4. This decision has raised fears that trade wars could return, weakening investor confidence. The move also cast doubt on the temporary trade truce reached with China in Switzerland last month. Trump accused China of breaking the deal, but China strongly denied it. It is still unclear whether the two leaders will meet soon. Kevin Hassett, head of the US National Economic Council, said a meeting between Trump and Chinese President Xi Jinping could happen later this week. However, markets are treating this possibility with caution. Some analysts believe the US does not plan to remove tariffs completely, but the lack of clear direction is adding long-term uncertainty. The dollar index is also under pressure from concerns about slowing US growth. According to Morgan Stanley (NYSE:MS), the US economy may weaken by mid-next year, leading to expected interest rate cuts. The bank predicts the dollar index (DXY) could drop nearly 9% to around 91—a level last seen during the pandemic. The economic data scheduled for this week will be key to where the US dollar heads next. Today, markets will watch both the US ISM manufacturing PMI and manufacturing PMI data from the Eurozone. Speeches from Federal Reserve members will also be closely followed for any hints about future interest rate moves. On Wednesday, the ADP private sector employment report and the Fed's Beige Book will be released. On Thursday, the foreign trade balance and unemployment claims data will come out. The most important data point of the week will be the US nonfarm payrolls report on Friday. These reports could strongly influence the Fed's short-term policy decisions. Analysts expect job growth to slow, but the unemployment rate is likely to hold steady at 4.2%. If the data show the labor market remains strong, fears of a recession may ease, and the dollar could bounce back. On the other hand, weaker job numbers may add more pressure on the dollar. Tensions on the geopolitical front are adding to the pressure on the US dollar. Over the weekend, Ukraine carried out a large drone strike on Russian military sites, reportedly damaging nearly 40 bombers. This renewed conflict has pushed investors toward safer assets. How Russia will respond remains uncertain. Talks are expected to take place in Istanbul, but the latest attacks raise doubts about the success of any diplomatic progress. Meanwhile, markets are also watching the European Central Bank's meeting on Thursday. The ECB is expected to cut interest rates by 25 basis points. While this puts some pressure on the euro, the move may still support the euro against the dollar, given the political and economic uncertainty in the US. In short, the dollar index is currently weighed down by trade tensions and signs of economic weakness. Geopolitical risks, unclear Fed policy, and especially renewed friction between the US and China will shape its direction. Friday's nonfarm payrolls data will be one of the most important indicators this week. Although the US Dollar slowed its downward trend last week, the developments over the weekend put pressure on the index again. As the US Dollar lost its intermediate support at 99, it started to slide below the level where it has found support since April. The current trend may lead the US Dollar to test the 97.90 level once again this week. On a weekly close below this level, the index will return to the falling channel that originated in February. Thus, in the coming months, we may see that the downtrend may continue towards the 95 region and then towards the 92 level. However, the easing of trade tensions and the data releases this week that are supportive of the US economy may help the US Dollar to find support in the 98 region again. In upward moves, daily closes above 99.65 can be followed as a sign of recovery. Then, the index may be expected to move towards the 100-102 region. However, the current outlook suggests that the US Dollar may continue its downward trend rather than a recovery. *** Be sure to check out InvestingPro to stay in sync with the market trend and what it means for your trading. Whether you're a novice investor or a seasoned trader, leveraging InvestingPro can unlock a world of investment opportunities while minimizing risks amid the challenging market AI: AI-selected stock winners with a proven track record. InvestingPro Fair Value: Instantly find out if a stock is underpriced or overvalued. Advanced Stock Screener: Search for the best stocks based on hundreds of selected filters and criteria. Top Ideas: See what stocks billionaire investors such as Warren Buffett, Michael Burry, and George Soros are buying. This article is written for informational purposes only. It is not intended to encourage the purchase of assets in any way, nor does it constitute a solicitation, offer, recommendation or suggestion to invest. I would like to remind you that all assets are evaluated from multiple perspectives and are highly risky, so any investment decision and the associated risk rests with the investor. We also do not provide any investment advisory services. Related articles US Dollar: This Week's Labor Data May Offer Support Despite Lingering Trade Fears US Dollar: Downside Risks Rise Amid Downbeat Economic Data Ahead of PCE This Week EUR/USD: Upside Momentum Builds as Rate Cut Delay Sparks Weakness in US Dollar Error in retrieving data Sign in to access your portfolio Error in retrieving data
Fast Company
20 minutes ago
- Fast Company
From immigration law to business success: Navigating the challenges for foreign business in the U.S.
As a U.S. business immigration attorney and founder of Grape Law Firm PLLC, I have worked with many foreign entrepreneurs who have achieved lasting success in the United States. Establishing and scaling a company here requires time, effort, and strategic planning to navigate a complex web of immigration regulations and compliance requirements. COMMON LEGAL HURDLES IN SECURING EMPLOYEE VISAS The primary challenge faced by businesspeople is securing a legal presence in the United States. This means obtaining the appropriate visa or status for both entrepreneurs and their essential personnel. However, the process of business immigration to the U.S. is often a challenging adventure. According to the 2024 CIS Ombudsman Annual Report, from initial market entry to business expansion—and even to permanent establishment—the complexities of business immigration affect entrepreneurs at every stage of their U.S. journey. They face significant challenges in documenting the viability of their enterprises to immigration officials while managing their immigration status to meet the changing needs of the business ecosystem. NAVIGATING VISA PATHWAYS FOR BUSINESS GROWTH As business immigration attorneys, one of our primary duties is to help our clients choose the most suitable visa for their business vision and goals. The selection of the appropriate visa is the foundation on which a successful application strategy is built and is an investment in the company's long-term growth. It is imperative for entrepreneurs to understand that various options exist for starting new businesses in the United States or expanding existing operations. Each visa category has its own distinct advantages and considerations based on differing business needs. For instance, the E‑1 Treaty Trader and the E‑2 Treaty Investor visas are viable options for entrepreneurs. These visa categories cater to foreign traders and investors who are citizens of treaty countries—countries that have treaty agreements with the U.S. Traders must engage in continuous trade with the United States, and the U.S. must be their primary trading partner. Conversely, investors must make substantial investments through new or existing enterprises. Both the E‑1 and E‑2 visas can support long-term, sustainable business ventures in the United States (each is valid for up to five years and can be extended indefinitely), provided that they spur economic progress in their respective industries and investment areas. Furthermore, the L‑1 Intracompany Transferee visa is an ideal choice for international companies planning to expand to the U.S. The L‑1 visa allows foreign companies to transfer their managerial or executive employees for new office openings, thereby facilitating the establishment of operations in the United States. However, a potential downside is that the L‑1 visa requires rigorous application preparation—a thorough case file must be compiled, followed by consistently detailed documentation of organizational development and business growth metrics, especially during the first three years of operations. A CASE IN POINT One case from our L‑1 visa practice perfectly illustrates these complexities. As a seasoned professional in the scaffolding industry, our client's initial L‑1 New Office visa application succeeded through careful preparation and a comprehensive five‑year business plan. However, the real challenges emerged during the extension phase. When she sought to extend her L‑1 visa with different legal counsel, she faced a rigorous Request for Evidence (RFE) from USCIS that scrutinized every aspect of her business operations. The RFE questioned not only the structure, but also its growth trajectory and staffing decisions—common challenges that many foreign businesses face in proving the legitimacy and sustainability of their operations. The industry's unique characteristics, including its project‑based nature and specialized staffing requirements, made it particularly challenging to conform to USCIS's traditional expectations for business development. Her case is a stark reminder for prospective entrepreneurs that experienced immigration counsel can provide needed guidance throughout the ups and downs of their U.S. immigration journey. Entrepreneurs must acknowledge that deciding on the right visa type is more than an entry ticket to the United States—a visa is the key to legal rights, business investments, and financial aspirations that influence one's life in the U.S. BUILDING A FOUNDATION FOR LONG-TERM SUCCESS The U.S. business immigration ecosystem is ever-changing and demands legal acumen in business planning—integrating proactive immigration solutions from the very beginning. To achieve lasting success, entrepreneurs need expert legal guidance to navigate the complex steps of immigration and adapt to any changes or updates in the immigration system. Beyond legal counsel, success often hinges on comprehensive preparation and strategic planning. Maintaining detailed business documentation from day one proves crucial for immigration success. Successful immigrant entrepreneurs often distinguish themselves through meticulous record-keeping of business transactions, employee contracts, and market analyses that demonstrate their enterprise's viability. Early strategic planning should include developing detailed business projections, establishing clear organizational structures, and creating systems for tracking achievements and metrics. These elements strengthen visa applications and create a foundation for sustainable growth. Networking within industry associations and chambers of commerce can provide valuable insights into immigration processes and business development. Furthermore, entrepreneurs who actively participate in their industry's ecosystem often find themselves better positioned to demonstrate their legitimacy to immigration authorities. This comprehensive approach, combining thorough documentation with strategic foresight, guarantees that immigration planning aligns with business goals while maintaining strict compliance with U.S. regulations. As we look to the future, business expansion into the United States and immigration to the country will only become more interlinked. In that regard, the aforementioned success story of our entrepreneur client is an excellent example—showcasing that viewing immigration not as a hurdle but as a strategic tool is essential for success. Always remember: proper planning, combined with expert guidance, can transform potential obstacles into opportunities for growth in the American market. The key to sustainable success lies in developing a nuanced understanding of how immigration pathways can support business objectives while ensuring compliance with regulatory requirements.
Forbes
21 minutes ago
- Forbes
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.
